Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer

[A2 Biotherapeutics, Inc.] A2 Biotherapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous patients with colorectal cancer that expresses carcinoembryonic antigen and has lost HLA-A*02 expression.

Intestinal Epithelial Krüppel-Like Factor 4 Alleviates Endotoxemia and Atherosclerosis through Improving NF-κB/miR-34a-Mediated Intestinal Permeability

[Acta Pharmacologica Sinica] The authors investigated the role of krüppel-like factor 4 in regulating intestinal inflammation and permeability during the atherosclerotic process.

Cancer Associated Fibroblasts-Derived SULF1 Promotes Gastric Cancer Metastasis and CDDP Resistance through the TGFBR3-Mediated TGF-β Signaling Pathway

[Cell Death Discovery] Scientists examined the role and underlying molecular mechanisms of human sulfatase 1 (SULF1) in the context of gastric cancer.

KCTD15 Acts as an Anti-tumor Factor in Colorectal Cancer Cells Downstream of the Demethylase FTO and the m6A Reader YTHDF2

[Communications Biology] Tetracycline induced overexpression and knockdown of potassium channel tetramerization domain containing 15 (KCTD15) confirms KCTD15 as an anti-proliferative and pro-apoptotic factor in colorectal cancer both in vitro and in xenografted tumors.

Intestinal Stem Cells: Guardians of Homeostasis in Health and Aging amid Environmental Challenges

[Experimental & Molecular Medicine] The authors explore the regulatory mechanisms that govern intestinal stem cell behavior, emphasizing the dynamic adaptability of the intestinal epithelium in the face of various challenges.

Small Molecules That Disrupt RAD54-BLM Interaction Hamper Tumor Proliferation in Colon Cancer Chemoresistance Models

[Journal Of Clinical Investigation] Chromatin immunoprecipitation sequencing analysis and validation revealed increased BLM/RAD54 co-recruitment on MRP2 promoter in camptothecin resistant colon cancer cells, leading to BLM-dependent enhancement of RAD54-mediated chromatin remodelling.

AMBRA1 Promotes Intestinal Inflammation by Antagonizing PP4R1/PP4c Mediated IKK Dephosphorylation in an Autophagy-Independent Manner

[Cell Death & Differentiation] Investigators found that autophagy/beclin-1 regulator 1 (AMBRA1) was highly expressed in inflamed colons in a colitis mouse model and in clinical inflammatory bowel disease samples.

BCL-XL Inhibitors Enhance the Apoptotic Efficacy of BRAF Inhibitors in BRAFV600E Colorectal Cancer

[Cell Death & Disease] Scientists discovered that BRAFV600E colorectal cancers (CRC) expressed high basal levels of the pro-survival proteins MCL-1 and BCL-XL, and that combining encorafenib with a BCL-XL inhibitor significantly enhanced apoptosis in BRAFV600E CRC cell lines.

E-Cadherin Loss Drives Diffuse-Type Gastric Tumorigenesis via EZH2-Mediated Reprogramming

[Journal Of Experimental Medicine] Researchers discovered CDH1 inactivation in a subset of diffuse-type gastric adenocarcinoma (DGAC) patient tumors. Analyzing single-cell transcriptomes in malignant ascites, they identified two DGAC subtypes: DGAC1 (CDH1 loss) and DGAC2 (lacking immune response).

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

[Cardiff Oncology] Cardiff Oncology, Inc. announced that the first patient was dosed in its randomized first-line Phase II trial, for patients with RAS-mutated metastatic colorectal cancer.

BeiGene’s Biologics License Application for Tevimbra® (Tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

[BeiGene] BeiGene, Ltd. announced that the US FDA has accepted a Biologics License Application for TEVIMBRA® , in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Tumor-Derived Exosomal ADAM17 Promotes Pre-Metastatic Niche Formation by Enhancing Vascular Permeability in Colorectal Cancer

[Journal of Experimental & Clinical Cancer Research] Investigators discovered that exosome-derived disintegrin and metalloproteinase 17 (ADAM17) derived from the circulating exosomes of patients with colorectal cancer could serve as a blood-based biomarker for predicting metastasis.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.

spot_img